MC2178A1 - Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants - Google Patents

Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants

Info

Publication number
MC2178A1
MC2178A1 MC89@@D MC2178D MC2178A1 MC 2178 A1 MC2178 A1 MC 2178A1 MC 2178 D MC2178 D MC 2178D MC 2178 A1 MC2178 A1 MC 2178A1
Authority
MC
Monaco
Prior art keywords
mutants
pneumolysin
pneumococcus
based vaccines
vaccines made
Prior art date
Application number
MC89@@D
Other languages
English (en)
French (fr)
Inventor
James Paton
David Hamsman
Graham Boulnois
Peter Andrew
Timothy Mitchell
John Walker
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Publication of MC2178A1 publication Critical patent/MC2178A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Current-Collector Devices For Electrically Propelled Vehicles (AREA)
  • Exchange Systems With Centralized Control (AREA)
MC89@@D 1988-12-16 1989-12-15 Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants MC2178A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPJ198988 1988-12-16
PCT/AU1989/000539 WO1990006951A1 (en) 1988-12-16 1989-12-15 Pneumolysin mutants and pneumococcal vaccines made therefrom

Publications (1)

Publication Number Publication Date
MC2178A1 true MC2178A1 (fr) 1992-05-22

Family

ID=3773589

Family Applications (1)

Application Number Title Priority Date Filing Date
MC89@@D MC2178A1 (fr) 1988-12-16 1989-12-15 Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants

Country Status (15)

Country Link
EP (1) EP0449856B1 (fi)
JP (1) JP3237842B2 (fi)
AT (1) ATE205534T1 (fi)
AU (1) AU626961B2 (fi)
BG (1) BG51358A3 (fi)
CA (1) CA2005704C (fi)
DE (1) DE68929323T2 (fi)
DK (1) DK173629B1 (fi)
ES (1) ES2160570T3 (fi)
FI (1) FI103122B (fi)
HU (1) HUT58804A (fi)
MC (1) MC2178A1 (fi)
NO (1) NO304317B1 (fi)
RU (1) RU2121481C1 (fi)
WO (1) WO1990006951A1 (fi)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716432B1 (en) * 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5391712A (en) * 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
US5928900A (en) * 1993-09-01 1999-07-27 The Rockefeller University Bacterial exported proteins and acellular vaccines based thereon
WO1995016711A1 (es) * 1993-12-17 1995-06-22 Universidad De Oviedo Anticuerpos contra la neumolisina y sus aplicaciones
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
HUP0002475A3 (en) * 1997-07-21 2002-01-28 Baxter Healthcare S A Wallisel Modified immunogenic pneumolysin compositions as vaccines
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
EP1880735A3 (en) * 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2189473A3 (en) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
JP2006500963A (ja) 2002-08-02 2006-01-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
WO2004039417A2 (en) 2002-11-01 2004-05-13 Glaxosmithkline Biologicals S.A. Drying process
AU2003291365B2 (en) 2002-11-07 2009-06-11 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
CA2518669C (en) 2003-03-13 2014-07-29 Glaxosmithkline Biologicals S.A. Purification process
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
WO2005032584A2 (en) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
CA2555803A1 (en) * 2004-02-13 2005-08-27 Sanofi Pasteur Limited Pneumolysin derivatives
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2005108419A1 (en) * 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
JP2008544949A (ja) 2004-10-08 2008-12-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 化膿性レンサ球菌のための免疫激性組成物および治療用組成物
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2636566C (en) 2006-01-17 2018-03-13 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2486938T (pt) 2006-09-26 2018-06-12 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
EP2086582B1 (en) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
KR101151202B1 (ko) 2006-10-12 2012-06-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 수중유 에멀젼 애주번트를 포함하는 백신
AU2008223951B2 (en) 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
AU2008287286B2 (en) * 2007-04-13 2013-10-10 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
CN101883583B (zh) 2007-06-26 2017-05-17 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
JP5656642B2 (ja) 2007-12-21 2015-01-21 ノバルティス アーゲー ストレプトリシンｏの変異体形態
EP2612680B1 (en) 2008-04-16 2018-05-23 GlaxoSmithKline Biologicals SA Vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
US8758766B2 (en) * 2008-12-24 2014-06-24 The Kingdom of The Netherlands, Represented by The Mininster of Health, Welfare and Sport, on Behalf of The Minster The National Institute of Public Health and The Environment Modified Streptococcus pneumoniae pneumolysin (PLY) polypeptides
JP5668049B2 (ja) 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
WO2011075822A1 (en) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions and related methods
AU2010335970B2 (en) * 2009-12-22 2016-11-03 Sanofi Pasteur Limited Immunogenic compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011112717A1 (en) 2010-03-09 2011-09-15 Biomedical Research Models, Inc. A novel mucosal vaccination approach for herpes simplex virus type-2
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20140072622A1 (en) 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
US9566325B2 (en) 2013-01-07 2017-02-14 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type-2 infections
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US11207396B2 (en) 2013-05-17 2021-12-28 The Board Of Regents Of The University Of Texas System Immunization to protect against adverse cardiac events relating to pneumococcal infection
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
PT3089754T (pt) 2013-12-31 2021-07-23 Infectious Disease Res Inst Formulações de vacina de dose única
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CA2968398A1 (en) 2014-11-21 2016-05-26 The Board Of Regents Of The University Of Oklahoma Pneumolysin mutants and methods of use thereof
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
CN109071665B (zh) 2016-04-18 2022-11-01 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
CA3023672A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
US11344619B2 (en) 2016-05-16 2022-05-31 Access To Advanced Health Institute Formulation containing TLR agonist and methods of use
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US20210198374A1 (en) 2018-04-17 2021-07-01 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
EP3919076A1 (en) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
AU2022253269A1 (en) 2021-04-09 2023-11-23 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Also Published As

Publication number Publication date
JPH04503948A (ja) 1992-07-16
DK115591D0 (da) 1991-06-14
EP0449856A1 (en) 1991-10-09
NO912226L (no) 1991-07-25
NO912226D0 (no) 1991-06-11
FI912878A0 (fi) 1991-06-14
BG51358A3 (en) 1993-04-15
DK115591A (da) 1991-08-14
DE68929323T2 (de) 2002-04-18
CA2005704C (en) 2003-02-11
AU4756490A (en) 1990-07-10
EP0449856A4 (en) 1992-05-20
EP0449856B1 (en) 2001-09-12
DK173629B1 (da) 2001-05-14
CA2005704A1 (en) 1990-06-16
FI103122B1 (fi) 1999-04-30
AU626961B2 (en) 1992-08-13
ATE205534T1 (de) 2001-09-15
FI103122B (fi) 1999-04-30
DE68929323D1 (de) 2001-10-18
RU2121481C1 (ru) 1998-11-10
JP3237842B2 (ja) 2001-12-10
WO1990006951A1 (en) 1990-06-28
HUT58804A (en) 1992-03-30
NO304317B1 (no) 1998-11-30
ES2160570T3 (es) 2001-11-16

Similar Documents

Publication Publication Date Title
MC2178A1 (fr) Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
GR3035081T3 (en) Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
PL291855A1 (en) Method of obtaining covalent conjugate of oligosaccharide with proteinous support
ZA898833B (en) Skin test and test kit for aids
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
EA199700419A1 (ru) Вакцинная композиция, содержащая полирибозилрибитолфосфат, и способ ее получения
Fattom et al. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates
EP0338265A3 (en) Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine
UA27754C2 (uk) Комбінована педіатрична вакцина, спосіб одночасної комбінованої вакцинації
ATE109004T1 (de) Toleranzinduktion gegenüber einem fremdantigen.
DK0636030T3 (da) Pasteurella haemolytica type A-1-bacterin-toxoid-vaccine
Schneerson et al. Bacterial capsular polysaccharide conjugates.
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen

Legal Events

Date Code Title Description
YP Annual fee paid